Log in

Relevant bibliographies by topics / Diffuse parenchymal lung diseases / Journal articles

To see the other types of publications on this topic, follow the link: Diffuse parenchymal lung diseases.

Journal articles on the topic 'Diffuse parenchymal lung diseases'

Author: Grafiati

Published: 4 June 2021

Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Diffuse parenchymal lung diseases.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tomassetti, Sara, Claudia Ravaglia, and Venerino Poletti. "Diffuse parenchymal lung disease." European Respiratory Review 26, no. 144 (April 26, 2017): 170004. http://dx.doi.org/10.1183/16000617.0004-2017.

Full text

Abstract:

Between September 2015 and August 2016 there were >1500 publications in the field of diffuse parenchymal lung diseases (DPLDs). For the Clinical Year in Review session at the European Respiratory Society Congress that was held in London, UK, in September 2016, we selected only five articles. This selection, made from the enormous number of published papers, does not include all the relevant studies that will significantly impact our knowledge in the field of DPLDs in the near future. This review article provides our personal view on the following topics: early diagnosis of idiopathic pulmonary fibrosis, current knowledge on the multidisciplinary team diagnosis of DPLDs and the diagnostic role of transbronchial cryobiopsy in this diagnostic setting, insights on the new entity of interstitial pneumonia with autoimmune features, and new therapeutic approaches for scleroderma-related interstitial lung disease.

APA, Harvard, Vancouver, ISO, and other styles

2

Poletti, Venerino, Claudia Ravaglia, and Sara Tomassetti. "Transbronchial cryobiopsy in diffuse parenchymal lung diseases." Current Opinion in Pulmonary Medicine 22, no. 3 (May 2016): 289–96. http://dx.doi.org/10.1097/mcp.0000000000000272.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Martinez, Fernando J., and Michael P. Keane. "Update in Diffuse Parenchymal Lung Diseases 2005." American Journal of Respiratory and Critical Care Medicine 173, no. 10 (May 15, 2006): 1066–71. http://dx.doi.org/10.1164/rccm.2601011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Raghunath, Sushravya, Srinivasan Rajagopalan, Ronald A. Karwoski, Fabien Maldonado, Tobias Peikert, Teng Moua, Jay H. Ryu, Brian J. Bartholmai, and Richard A. Robb. "Quantitative Stratification of Diffuse Parenchymal Lung Diseases." PLoS ONE 9, no. 3 (March 27, 2014): e93229. http://dx.doi.org/10.1371/journal.pone.0093229.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Walsh, Sinead M., and Anthony W. O’Regan. "Diffuse Parenchymal Lung Diseases in the Elderly." Current Geriatrics Reports 7, no. 3 (July 13, 2018): 174–80. http://dx.doi.org/10.1007/s13670-018-0249-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Shlobin, Oksana A., A. Whitney Brown, and Steven D. Nathan. "Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases." Chest 151, no. 1 (January 2017): 204–14. http://dx.doi.org/10.1016/j.chest.2016.08.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Farag, TaghreedS, ZeinabR Adawy, LobnaK Sakr, and HanaaS Abdellateef. "Transthoracic ultrasonographic features of diffuse parenchymal lung diseases." Egyptian Journal of Bronchology 11, no. 3 (2017): 179. http://dx.doi.org/10.4103/ejb.ejb_3_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Tsangaris, Iraklis, Georgios Tsaknis, Anastasia Anthi, and Stylianos E. Orfanos. "Pulmonary Hypertension in Parenchymal Lung Disease." Pulmonary Medicine 2012 (2012): 1–14. http://dx.doi.org/10.1155/2012/684781.

Full text

Abstract:

Idiopathic pulmonary arterial hypertension (IPAH) has been extensively investigated, although it represents a less common form of the pulmonary hypertension (PH) family, as shown by international registries. Interestingly, in types of PH that are encountered in parenchymal lung diseases such as interstitial lung diseases (ILDs), chronic obstructive pulmonary disease (COPD), and many other diffuse parenchymal lung diseases, some of which are very common, the available data is limited. In this paper, we try to browse in the latest available data regarding the occurrence, pathogenesis, and treatment of PH in chronic parenchymal lung diseases.

APA, Harvard, Vancouver, ISO, and other styles

9

Braun, Sarah, Marion Ferner, Kai Kronfeld, and Matthias Griese. "Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases." Pediatric Pulmonology 50, no. 4 (December 9, 2014): 410–19. http://dx.doi.org/10.1002/ppul.23133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Pulagam, Ammi Reddy, Giri Babu Kande, Venkata Krishna Rao Ede, and Ramesh Babu Inampudi. "Automated Lung Segmentation from HRCT Scans with Diffuse Parenchymal Lung Diseases." Journal of Digital Imaging 29, no. 4 (March 9, 2016): 507–19. http://dx.doi.org/10.1007/s10278-016-9875-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Baldi, Bruno Guedes, Carlos Roberto Ribeiro Carvalho, Olívia Meira Dias, Edson Marchiori, and Bruno Hochhegger. "Diffuse cystic lung diseases: differential diagnosis." Jornal Brasileiro de Pneumologia 43, no. 2 (April 2017): 140–49. http://dx.doi.org/10.1590/s1806-37562016000000341.

Full text

Abstract:

ABSTRACT Diffuse cystic lung diseases are characterized by cysts in more than one lung lobe, the cysts originating from various mechanisms, including the expansion of the distal airspaces due to airway obstruction, necrosis of the airway walls, and parenchymal destruction. The progression of these diseases is variable. One essential tool in the evaluation of these diseases is HRCT, because it improves the characterization of pulmonary cysts (including their distribution, size, and length) and the evaluation of the regularity of the cyst wall, as well as the identification of associated pulmonary and extrapulmonary lesions. When combined with clinical and laboratory findings, HRCT is often sufficient for the etiological definition of diffuse lung cysts, avoiding the need for lung biopsy. The differential diagnoses of diffuse cystic lung diseases are myriad, including neoplastic, inflammatory, and infectious etiologies. Pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, lymphocytic interstitial pneumonia, and follicular bronchiolitis are the most common diseases that produce this CT pattern. However, new diseases have been included as potential determinants of this pattern.

APA, Harvard, Vancouver, ISO, and other styles

12

Batra, Kiran, Riham Dessouky, YasmeenM Butt, Vibhor Wadhwa, JoseR Torrealba, and Craig Glazer. "Series of rare lung diseases mimicking imaging patterns of common diffuse parenchymal lung diseases." Lung India 35, no. 3 (2018): 231. http://dx.doi.org/10.4103/lungindia.lungindia_291_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Narender, Methuku, Manikanta Dhanamurthy Koppu, Vavilala Satish Kumar Rao, Auzumeedi Sai Kumar, Subhakar Kandi, and Surya Kiran Pulivarthi. "ROLE OF TRANS BRON CHIAL LUNG BIOPSY IN DIFFUSE PARENCHYMAL LUNG DISEASES." Journal of Evolution of Medical and Dental Sciences 4, no. 69 (August 25, 2015): 11924–30. http://dx.doi.org/10.14260/jemds/2015/1721.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Dikensoy, Oner, Resat Kervancioglu, Ibrahim Ege, Nevin Uysal, Osman Elbek, and Ayhan Ozkur. "High Prevalence of Diffuse Parenchymal Lung Diseases among Turkish Tinners." Journal of Occupational Health 50, no. 2 (March 2008): 208–11. http://dx.doi.org/10.1539/joh.l7104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Cinel, Güzin, Nural Kiper, Diclehan Orhan, Nagehan Emiralioğlu, Ebru Yalçın, Deniz Doğru, Uğur Özçelik, Berna Oğuz, and Mithat Haliloğlu. "Childhood diffuse parenchymal lung diseases: We need a new classification." Clinical Respiratory Journal 14, no. 2 (December 8, 2019): 102–8. http://dx.doi.org/10.1111/crj.13106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Kln??, G??nseli, and Elif Altu?? Kolsuk. "The role of bronchoalveolar lavage in diffuse parenchymal lung diseases." Current Opinion in Pulmonary Medicine 11, no. 5 (September 2005): 417–21. http://dx.doi.org/10.1097/01.mcp.0000175522.49353.e1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Meng, Peng, Gan Liang Tan, Su Ying Low, Angela Takano, Yuen Li Ng, and Devanand Anantham. "Fibered Confocal Fluorescence Microscopy Imaging in Diffuse Parenchymal Lung Diseases." Chest 148, no. 4 (October 2015): 788A. http://dx.doi.org/10.1378/chest.2254272.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Canıvar, Coşkun, Züleyha Bingöl, Zeki Kılıçaslan, Tülin Çağatay, and N. Gülfer Okumuş. "Investigation of parameters related to prognosis in diffuse parenchymal lung diseases prognosis in interstitial lung diseases." Tuberkuloz ve Toraks 65, no. 3 (September 30, 2017): 210–19. http://dx.doi.org/10.5578/tt.57501.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Alapati, Deepthi, William J. Zacharias, Heather A. Hartman, Avery C. Rossidis, John D. Stratigis, Nicholas J. Ahn, Barbara Coons, et al. "In utero gene editing for monogenic lung disease." Science Translational Medicine 11, no. 488 (April 17, 2019): eaav8375. http://dx.doi.org/10.1126/scitranslmed.aav8375.

Full text

Abstract:

Monogenic lung diseases that are caused by mutations in surfactant genes of the pulmonary epithelium are marked by perinatal lethal respiratory failure or chronic diffuse parenchymal lung disease with few therapeutic options. Using a CRISPR fluorescent reporter system, we demonstrate that precisely timed in utero intra-amniotic delivery of CRISPR-Cas9 gene editing reagents during fetal development results in targeted and specific gene editing in fetal lungs. Pulmonary epithelial cells are predominantly targeted in this approach, with alveolar type 1, alveolar type 2, and airway secretory cells exhibiting high and persistent gene editing. We then used this in utero technique to evaluate a therapeutic approach to reduce the severity of the lethal interstitial lung disease observed in a mouse model of the human SFTPCI73T mutation. Embryonic expression of SftpcI73T alleles is characterized by severe diffuse parenchymal lung damage and rapid demise of mutant mice at birth. After in utero CRISPR-Cas9–mediated inactivation of the mutant SftpcI73T gene, fetuses and postnatal mice showed improved lung morphology and increased survival. These proof-of-concept studies demonstrate that in utero gene editing is a promising approach for treatment and rescue of monogenic lung diseases that are lethal at birth.

APA, Harvard, Vancouver, ISO, and other styles

20

Ghigna, Maria Rosa, Wolter J. Mooi, and Katrien Grünberg. "Pulmonary hypertensive vasculopathy in parenchymal lung diseases and/or hypoxia." European Respiratory Review 26, no. 144 (June 28, 2017): 170003. http://dx.doi.org/10.1183/16000617.0003-2017.

Full text

Abstract:

Pulmonary hypertension (PH) with complicating chronic lung diseases and/or hypoxia falls into group 3 of the updated classification of PH. Patients with chronic obstructive lung disease (COPD), diffuse lung disease (such as idiopathic pulmonary fibrosis (IPF)) and with sleep disordered breathing are particularly exposed to the risk of developing PH. Although PH in such a context is usually mild, a minority of patients exhibit severe haemodynamic impairment, defined by a mean pulmonary arterial pressure (mPAP) of ≥35 mmHg or mPAP values ranging between 25 mmHg and 35 mmHg with a low cardiac index (<2 L·min−1·m−2). The overlap between lung parenchymal disease and PH heavily affects life expectancy in such a patient population and complicates their therapeutic management. In this review we illustrate the pathological features and the underlying pathophysiological mechanisms of pulmonary circulation in chronic lung diseases, with an emphasis on COPD, IPF and obstructive sleep apnoea syndrome.

APA, Harvard, Vancouver, ISO, and other styles

21

ÇIRAK, Ali Kadri, Nuran KATGI, Onur Fevzi ERER, Pınar ÇİMEN, Fatma Fevziye TUKSAVUL, and Burçin HAKOĞLU. "Diagnostic approach in parenchymal lung diseases: transbronchial lung biopsy or cryobiopsy?" TURKISH JOURNAL OF MEDICAL SCIENCES 50, no. 6 (October 22, 2020): 1535–39. http://dx.doi.org/10.3906/sag-1910-47.

Full text

Abstract:

Background/aim: Diagnosis of interstitial lung diseases requires a multidisciplinary approach, and a gold standard for histological diagnosis is open lung biopsy. Transbronchial lung biopsy (TBLB) and in recent years an alternative method, cryobiopsy (TBLC), are used for the diagnosis of parenchymal lung lesions. The aim of this study is to compare the efficacy of concomitant conventional TBLB and TBLC.Materials and methods: A total of 82 patients who underwent TBLC for diagnosis of diffuse parenchymal lung diseases at Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital between 2015 and 2018 were screened retrospectively and included in the study. Of the patients, 53.7% (n: 44) were male, and 46.4% (n:38) of them were female. The mean age was 58.37 (±9.33) years. First TBLB and then TBLC were performed to all patients in the same session and their diagnostic performances were compared.Results: Although both procedures were done in the same session, 45 patients (54.9%) were diagnosed with TBLB and 75 patients (91.5%) were diagnosed with TBLC (P ˂ 0.001). Hemorrhage was observed in 39 patients (47.6%), but only one had a massive hemorrhage. Pneumothorax was observed in 6 patients (7.3%) and none of them required tube drainage.Conclusion: Transbronchial lung cryobiopsy is a promising technique for the diagnosis of parenchymal lung diseases compared to transbronchial lung biopsy.

APA, Harvard, Vancouver, ISO, and other styles

22

Abdelsalam, Etemad, MagdyM Omar, AhmadS Alhalafawy, NashwaM Emara, and MohammadA E. El-Mahdy. "The role of medical thoracoscopic lung biopsy in diagnosis of diffuse parenchymal lung diseases." Egyptian Journal of Bronchology 13, no. 2 (2019): 155. http://dx.doi.org/10.4103/ejb.ejb_41_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Shafiek, Hanaa, Shaimaa Elbialy, Samar Nabil Elachy, and Ahmed Youssef Gad. "Transbronchial cryobiopsy validity in diagnosing diffuse parenchymal lung diseases in Egyptian population." Journal of Multidisciplinary Healthcare Volume 12 (August 2019): 719–26. http://dx.doi.org/10.2147/jmdh.s208824.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Yadav, Dr Harendra, and Dr Rahul Srivastava. "Clinicoradiological and demographic pattern in diffuse parenchymal lung diseases: An observational study." International Journal of Medical Research and Review 6, no. 6 (August 31, 2018): 308–14. http://dx.doi.org/10.17511/ijmrr.2018.i06.03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Verrastro, Carlos Gustavo Yuji, Viviane Baptista Antunes, Dany Jasinowodolinski, Giuseppe DʼIppolito, and Gustavo de Souza Portes Meirelles. "High-Resolution Computed Tomography in the Diagnosis of Diffuse Parenchymal Lung Diseases." Journal of Computer Assisted Tomography 40, no. 2 (2016): 248–55. http://dx.doi.org/10.1097/rct.0000000000000344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kulshrestha, Ritu, Himanshu Dhanda, Apoorva Pandey, Amit Singh, and Raj Kumar. "Immunopathogenesis and therapeutic potential of macrophage influx in diffuse parenchymal lung diseases." Expert Review of Respiratory Medicine 14, no. 9 (June 30, 2020): 917–28. http://dx.doi.org/10.1080/17476348.2020.1776117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Urban, Jan, Magda Suchankova, Martina Ganovska, Vladimir Leksa, Frantisek Sandor, Eva Tedlova, Brian Konig, and Maria Bucova. "The Role of CX3CL1 and ADAM17 in Pathogenesis of Diffuse Parenchymal Lung Diseases." Diagnostics 11, no. 6 (June 11, 2021): 1074. http://dx.doi.org/10.3390/diagnostics11061074.

Full text

Abstract:

Fractalkine (CX3CL1) is a unique chemokine that functions as a chemoattractant for effector cytotoxic lymphocytes and macrophages expressing fractalkine receptor CX3CR1. CX3CL1 exists in two forms—a soluble and a membrane-bound form. The soluble CX3CL1 is released from cell membranes by proteolysis by the TNF-α-converting enzyme/disintegrin-like metalloproteinase 17 (TACE/ADAM17) and ADAM10. In this study, we evaluated the diagnostic relevance and potential roles of CX3CL1 and ADAM17 in the pathogenesis of diffuse parenchymal lung diseases (DPLDs) in the human population. The concentration of CX3CL1 and ADAM17 was measured by the enzyme-linked immunosorbent assay (ELISA) test in bronchoalveolar lavage fluids of patients suffering from different DPLDs. The concentration of CX3CL1 was significantly higher in patients suffering from idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis patients compared to the control group. A significantly higher concentration of CX3CL1 was measured in fibrotic DPLDs compared to non-fibrotic DLPD patients. We found a positive correlation of CX3CL1 levels with the number of CD8+ T cells, and a negative correlation with CD4+ T cells in BALF and diffusion capacity for carbon monoxide. The concentration of ADAM17 was significantly lower in the IPF group compared to the other DPLD groups. We noticed a significantly higher CX3CL1/ADAM17 ratio in the IPF group compared to the other DPLD groups. We suggest that CX3CL1 has a distinctive role in the pathogenesis of DPLDs. The level of CX3CL1 strongly correlates with the severity of lung parenchyma impairment. The results suggest that high values of CX3CL1/ADAM17 could be diagnostic markers for IPF.

APA, Harvard, Vancouver, ISO, and other styles

28

Viglietta, Luca, Riccardo Inchingolo, Cristina Pavano, Sara Tomassetti, Sara Piciucchi, Andrea Smargiassi, Claudia Ravaglia, et al. "Ultrasonography for the Diagnosis of Pneumothorax after Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases." Respiration 94, no. 2 (2017): 232–36. http://dx.doi.org/10.1159/000477818.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Wuyts, Wim. "Surgical lung biopsy is not the golden standard in diagnosis of diffuse parenchymal lung diseases." European Journal of Cardio-Thoracic Surgery 34, no. 6 (December 2008): 1271–72. http://dx.doi.org/10.1016/j.ejcts.2008.09.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Bondue, Benjamin, Thierry Pieters, Patrick Alexander, Paul De Vuyst, Maria Ruiz Patino, Delphine Hoton, Myriam Remmelink, and Dimitri Leduc. "Role of Transbronchial Lung Cryobiopsies in Diffuse Parenchymal Lung Diseases: Interest of a Sequential Approach." Pulmonary Medicine 2017 (2017): 1–7. http://dx.doi.org/10.1155/2017/6794343.

Full text

Abstract:

Background. Transbronchial lung cryobiopsies (TBLCs) are a promising diagnostic tool in the setting of diffuse parenchymal lung diseases (DPLDs). However, no comparison with surgical lung biopsy (SLB) in the same patient is available. Methods. The diagnostic yield and safety data of TBLCs, as well as the result of SLB performed after TBLCs, were analysed in a multicentric Belgian study. A SLB was performed after TBLCs in absence of a definite pathological diagnosis or if a NSIP pattern was observed without related condition identified following multidisciplinary discussion. Results. Between April 2015 and November 2016, 30 patients were included. Frequent complications included pneumothorax (20%) and bleeding (severe 7%, moderate 33%, and mild 53%). There was no mortality. The overall diagnostic yield was 80%. A SLB was performed in six patients (three without definite histological pattern and three with an NSIP). The surgical biopsy changed the pathological diagnosis into a UIP pattern in five patients and confirmed a NSIP pattern in one patient. Conclusion. TBLCs are useful in the diagnostic work-up of DPLDs avoiding a SLB in 80% of the patients. However, surgical biopsies, performed as a second step after TBLCs because of an indefinite diagnosis or a NSIP pattern, provide additional information supporting the interest of a sequential approach in these patients.

APA, Harvard, Vancouver, ISO, and other styles

31

Biswas, Muhammad Asaduzzaman, Muhammad Nazrul Islam, Khalifa Mahmud Walid, and Zhilam Zia Rassel. "Case Report of Diffuse Parenchymal Lung Disease with Non-Specific Interstitial Pneumonia Pattern and Good Response to Treatment." Faridpur Medical College Journal 13, no. 2 (October 20, 2019): 101–3. http://dx.doi.org/10.3329/fmcj.v13i2.43646.

Full text

Abstract:

The diffuse parenchymal lung diseases (DPLDs) are a heterogeneous group of conditions affecting the pulmonary parenchyma (interstitial) and/or alveolar lumen. IPF (Idiopathic Pulmonary Fibrosis) is a chronic interstitial pneumonia of unknown causes. It is commonest form of DPLD but its treatment response is very poor. On the other hand, NSIP (Non-Specific Interstitial Pneumonia) can still be a variant of DPLD with better treatment response and prognosis. Here we discussed a young female with NSIP with good response to steroid. Faridpur Med. Coll. J. Jul 2018;13(2): 101-103

APA, Harvard, Vancouver, ISO, and other styles

32

Aboudara, Matthew, and Fabien Maldonado. "Transbronchial cryobiopsy for diffuse parenchymal lung diseases: evidence that demands a (favorable) verdict." Annals of Translational Medicine 8, no. 20 (October 2020): 1324. http://dx.doi.org/10.21037/atm-20-2995.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Li, Diandian, Bo Wang, Yi Liu, and Haohua Wang. "Prevalence and impact of comorbid obstructive sleep apnoea in diffuse parenchymal lung diseases." PLOS ONE 16, no. 2 (February 11, 2021): e0246878. http://dx.doi.org/10.1371/journal.pone.0246878.

Full text

Abstract:

Objective Obstructive sleep apnea (OSA) are increasingly recognized as important features in diffuse parenchymal lung diseases (DPLDs) with differed prevalence and impact reported. The aim of this study is to systematically review the prevalence of comorbid OSA and characterize its impact on clinical and outcome measurements in adults with DPLDs. Methods Publications addressing the prevalence of OSA in DPLDs and its impacts on DPLDs were selected from electronic databases. A random-effect model was used to estimate the pooled prevalence of OSA. Odds ratios (ORs) or mean differences (MDs) were used to assess the associations of OSA with clinical and outcome measurements. Heterogeneity was quantified by I2 with 95% confidence interval (95% CI). Results 4 studies comprising 643 participants were included. Overall, the pooled prevalence of OSA among DPLDs was 72% (95% CI: 65–79%; I2 = 75.4%). Moderate-severe OSA was observed in 40% patients (95% CI: 28–52%; I2 = 90.8%). The prevalence was higher as 76% in idiopathic pulmonary fibrosis (IPF) patients than in connective tissue associated-ILD or sarcoidosis (60%). Although oxygen desaturation during sleep was greater in OSA group compared with non-OSA patients, there was no difference in lung function or systematic comorbidities between the two groups. The associations between OSA and the mortality or disease progression of DPLDs were also systematically reviewed. Conclusion In conclusion, OSA is a common comorbidity in DPLD patients, affecting approximately three in four patients, which may exacerbate the nocturnal desaturation and have negative influence on the outcomes. Larger studies with more homogeneous samples are warranted.

APA, Harvard, Vancouver, ISO, and other styles

34

Alfaro, Tiago M., Catharina C. Moor, Veronica Alfieri, Florence Jeny, Michael Kreuter, Marlies S. Wijsenbeek, Elisabetta A. Renzoni, et al. "Research highlights from the 2018 ERS International Congress: interstitial lung diseases." ERJ Open Research 5, no. 1 (February 2019): 00215–2018. http://dx.doi.org/10.1183/23120541.00215-2018.

Full text

Abstract:

This article reviews a selection of the scientific presentations on interstitial lung disease (ILD)/diffuse parenchymal lung disease (DPLD) that were made at the 2018 European Respiratory Society (ERS) International Congress in Paris. A number of advances in the epidemiology, pathogenesis, diagnosis and treatment of these disorders were presented and discussed by clinicians and researchers. The research topics span over all four groups of ERS Assembly 12: Interstitial Lung Diseases (Group 12.01: Idiopathic interstitial pneumonias; Group 12.02: ILD/DPLD of known origin; Group 12.03: Sarcoidosis and other granulomatous ILD/DPLD; Group 12.04: Rare ILD/DPLD).

APA, Harvard, Vancouver, ISO, and other styles

35

Aquilina, Giulia, Daniele Carmelo Caltabiano, Federica Galioto, Giovanna Cancemi, Fabio Pino, Ada Vancheri, Carlo Vancheri, Pietro Valerio Foti, Letizia Antonella Mauro, and Antonio Basile. "Cystic Interstitial Lung Diseases: A Pictorial Review and a Practical Guide for the Radiologist." Diagnostics 10, no. 6 (May 27, 2020): 346. http://dx.doi.org/10.3390/diagnostics10060346.

Full text

Abstract:

A cyst is a round circumscribed area of low attenuation, surrounded by epithelial or fibrous wall. Cysts can frequently occur on chest computed tomography (CT) and high-resolution computed tomography (HRCT); multiple parenchymal cysts of the lungs are the most typical feature of cystic lung interstitial diseases, characterizing a wide spectrum of diseases—ranging from isolated lung disorders up to diffuse pulmonary diseases. The aim of this review is to analyze scientific literature about cystic lung interstitial diseases and to provide a practical guide for radiologists, focusing on the main morphological features of pulmonary cysts: size, shape, borders, wall, location, and distribution. These features are shown on free-hand drawings and related to HRCT images, in order to help radiologists pursue the correct differential diagnosis between similar conditions.

APA, Harvard, Vancouver, ISO, and other styles

36

Cony, Fernanda G., Fernando F. Argenta, Lilian C. Heck, Leticia F. Moreira, Fernanda V. A. Costa, Luciana Sonne, and Saulo P. Pavarini. "Clinical and pathological aspects of idiopathic pulmonary fibrosis in cats." Pesquisa Veterinária Brasileira 39, no. 2 (February 2019): 134–41. http://dx.doi.org/10.1590/1678-5150-pvb-5942.

Full text

Abstract:

ABSTRACT: Interstitial lung diseases are a group of diffuse parenchymal lung diseases that include interstitial lung fibrosis. The aim of this study is to characterize the clinical and pathological findings of idiopathic pulmonary fibrosis in three cats and to investigate possible etiological agents through bacteriological and mycological exams and immunohistochemistry. All three cats were female and aged from 10 to 14 years old, they presented with a clinical history of weight loss and dyspnea. The radiographic changes were similar in all cats and included increased pulmonary radiopacity with a mixed bronchointerstitial pattern progressing to an alveolar pattern. Two cats died during lung biopsy procedures. At necropsy, the lesions were limited to the pulmonary parenchyma and were firm, hypocrepitant with a multinodular appearance on the pleural surface; they failed to completely collapse when the thorax was opened. In the pleural region, there were multifocal star-shaped scarring lesions, with parenchymal retraction. Microscopically, all three cats had multifocal-to-coalescing fibrosis, type II pneumocyte hyperplasia, hypertrophy or hyperplasia of the smooth muscle tissue of terminal bronchioles and an accumulation of macrophages within the alveolar spaces. There was no growth on bacteriological or mycological cultures, and the immunohistochemical evaluations for the presence of viral etiological agents (FIV, FeLV, FCoV, FCV and FHV-1) were also negative.

APA, Harvard, Vancouver, ISO, and other styles

37

KARADOĞAN, Dilek, and Göksel ALTINIŞIK. "The Evaluation of Patients Diagnosed as Diffuse Parenchymal Lung Diseases Between Years 2005-2010." Turkiye Klinikleri Journal of Health Sciences 4, no. 1 (2019): 34–42. http://dx.doi.org/10.5336/healthsci.2018-62248.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Casoni, G. L., C. R. Cordeiro, S. Tomassetti, M. Romagnoli, M. Chilosi, A. Cancellieri, C. Gurioli, and V. Poletti. "The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: Pro." Revista Portuguesa de Pneumologia (English Edition) 18, no. 2 (March 2012): 57–60. http://dx.doi.org/10.1016/j.rppnen.2011.03.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Margaritopoulos, G. A., and A. U. Wells. "The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: Con." Revista Portuguesa de Pneumologia (English Edition) 18, no. 2 (March 2012): 61–63. http://dx.doi.org/10.1016/j.rppnen.2011.09.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Casoni, G. L., C. R. Cordeiro, S. Tomassetti, M. Romagnoli, M. Chilosi, A. Cancellieri, C. Gurioli, and V. Poletti. "The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: Pro." Revista Portuguesa de Pneumologia 18, no. 2 (March 2012): 57–60. http://dx.doi.org/10.1016/j.rppneu.2011.05.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Margaritopoulos, G. A., and A. U. Wells. "The role of transbronchial biopsy in the diagnosis of diffuse parenchymal lung diseases: Con." Revista Portuguesa de Pneumologia 18, no. 2 (March 2012): 61–63. http://dx.doi.org/10.1016/j.rppneu.2011.09.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Maldonado, Fabien, and Jay H. Ryu. "Surgical Biopsy for Diffuse Parenchymal Lung Diseases: Are We Causing More Harm Than Good?" Journal of Bronchology & Interventional Pulmonology 16, no. 4 (October 2009): 227–28. http://dx.doi.org/10.1097/lbr.0b013e3181bb7371.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Samarelli, Anna Valeria, Roberto Tonelli, Alessandro Marchioni, Giulia Bruzzi, Filippo Gozzi, Dario Andrisani, Ivana Castaniere, et al. "Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players." International Journal of Molecular Sciences 22, no. 16 (August 19, 2021): 8952. http://dx.doi.org/10.3390/ijms22168952.

Full text

Abstract:

Interstitial lung diseases (ILDs) that are known as diffuse parenchymal lung diseases (DPLDs) lead to the damage of alveolar epithelium and lung parenchyma, culminating in inflammation and widespread fibrosis. ILDs that account for more than 200 different pathologies can be divided into two groups: ILDs that have a known cause and those where the cause is unknown, classified as idiopathic interstitial pneumonia (IIP). IIPs include idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP) known also as bronchiolitis obliterans organizing pneumonia (BOOP), acute interstitial pneumonia (AIP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), and lymphocytic interstitial pneumonia (LIP). In this review, our aim is to describe the pathogenic mechanisms that lead to the onset and progression of the different IIPs, starting from IPF as the most studied, in order to find both the common and standalone molecular and cellular key players among them. Finally, a deeper molecular and cellular characterization of different interstitial lung diseases without a known cause would contribute to giving a more accurate diagnosis to the patients, which would translate to a more effective treatment decision.

APA, Harvard, Vancouver, ISO, and other styles

44

Ryu, Jay H., Teng Moua, Natalya Azadeh, Misbah Baqir, and Eunhee S. Yi. "Current concepts and dilemmas in idiopathic interstitial pneumonias." F1000Research 5 (November 10, 2016): 2661. http://dx.doi.org/10.12688/f1000research.9601.1.

Full text

Abstract:

Idiopathic interstitial pneumonias comprise approximately one-third of interstitial lung diseases (also called diffuse parenchymal infiltrative lung diseases). The classification of idiopathic interstitial pneumonias has undergone several revisions since the initial description of 40 years ago, and the most recent version was published in 2013. Although some aspects have been clarified, this group of heterogeneous disorders continues to be a source of confusion and misunderstanding in clinical applications. In this article, we explore several topical themes in the evaluation and management of patients with idiopathic interstitial pneumonias.

APA, Harvard, Vancouver, ISO, and other styles

45

Szturmowicz, Monika, Aneta Kacprzak, and Jan Kuś. "Pulmonary hypertension in diffuse parenchymal lung diseases — is there any benefit of PAH-specific therapy?" Advances in Respiratory Medicine 85, no. 4 (September 5, 2017): 216–23. http://dx.doi.org/10.5603/arm.2017.0036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Xu, Dan, Zhimin Chen, Huizhong Chen, Rongyan Huang, Shunying Zhao, Xiuyun Liu, Chunju Zhou, et al. "Application of Clinico-Radiologic-Pathologic Diagnosis of Diffuse Parenchymal Lung Diseases in Children in China." PLOS ONE 10, no. 1 (January 8, 2015): e0116930. http://dx.doi.org/10.1371/journal.pone.0116930.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Flamein, Florence, Laure Riffault, Céline Muselet-Charlier, Julie Pernelle, Delphine Feldmann, Laurence Jonard, Anne-Marie Durand-Schneider, et al. "Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children." Human Molecular Genetics 21, no. 4 (November 7, 2011): 765–75. http://dx.doi.org/10.1093/hmg/ddr508.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Wuyts, Wim A., and Geert M. Verleden. "Integration of Clinical, Radiological, and Histopathological Data in the Diagnosis of Diffuse Parenchymal Lung Diseases." American Journal of Respiratory and Critical Care Medicine 179, no. 3 (February 2009): 254–55. http://dx.doi.org/10.1164/ajrccm.179.3.254b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

MASSOPTIER, LAURENT, AVISHKAR MISRA, ARCOT SOWMYA, and SERGIO CASCIARO. "COMBINING GRAPH-CUT TECHNIQUE AND ANATOMICAL KNOWLEDGE FOR AUTOMATIC SEGMENTATION OF LUNGS AFFECTED BY DIFFUSE PARENCHYMAL DISEASE IN HRCT IMAGES." International Journal of Image and Graphics 11, no. 04 (October 2011): 509–29. http://dx.doi.org/10.1142/s0219467811004202.

Full text

Abstract:

Accurate and automated lung segmentation in high-resolution computed tomography (HRCT) is highly challenged by the presence of pathologies affecting lung parenchyma appearance and borders. The algorithm presented employs an anatomical model-driven approach and systematic incremental knowledge acquisition to produce coarse lung delineation, used as initialization for the graph-cut algorithm. The proposed method is evaluated on a 49 HRCT cases dataset including various lung disease patterns. The accuracy of the method is assessed using dice similarity coefficient (DSC) and shape differentiation metrics (d mean , d rms ), by comparing the outputs of automatic lung segmentations and manual ones. The proposed automatic method demonstrates high segmentation accuracy ( DSC = 96.64%, d mean = 1.75 mm, d rms = 3.27 mm) with low variation that depends on the lung disease pattern. It also presents good improvement over the initial lung segmentation (Δ DSC = 4.74%, Δd mean = -3.67 mm, Δd rms = -6.25 mm), including impressive amelioration (maximum values of Δ DSC = 58.22% and Δd mean = -78.66 mm) when the anatomy-driven algorithm reaches its limit. Segmentation evaluation shows that the method can accurately segment lungs even in the presence of disease patterns, with some limitations in the apices and bases of lungs. Therefore, the developed automatic segmentation method is a good candidate for the first stage of a computer-aided diagnosis system for diffuse lung diseases.

APA, Harvard, Vancouver, ISO, and other styles

50

Dupin, Clairelyne, Vânia Fernandes, Fernanda Hernandez-Gonzalez, Sebastiano Emanuele Torrisi, Tiago M. Alfaro, Michael Kreuter, Marlies S. Wijsenbeek, et al. "ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly." ERJ Open Research 6, no. 4 (October 2020): 00143–2020. http://dx.doi.org/10.1183/23120541.00143-2020.

Full text

Abstract:

This article discusses a selection of the scientific presentations in the field of interstitial lung diseases (ILDs) that took place at the 2019 European Respiratory Society International Congress in Madrid, Spain. There were sessions from all four groups within Assembly 12: group 12.01 “Idiopathic interstitial pneumonias”, group 12.02 “ILDs/diffuse parenchymal lung diseases (DPLDs) of known origin”, group 12.03 “Sarcoidosis and other granulomatous ILDs/DPLDs” and group 12.04 “Rare ILDs/DPLDs”. The presented studies brought cutting-edge developments on several aspects of these conditions, including pathogenesis, diagnosis and treatment. As many of the ILDs are individually rare, the sharing of experiences and new data that occur during the Congress are very important for physicians interested in ILDs and ILD patients alike.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!